

Product range: Assay Genie Anti-Drug Antibody Range (GXDA series) — PBS formulation | **SDS no.:** GXDA_MSDS_PBS |
Revision: Version 1.0 | **Revision date:** 28 July 2026 | **Products covered:** 150

SECTION 1: Identification of the substance/mixture and of the company/undertaking

Product identifier	Assay Genie anti-drug antibody (product/SKU code in the format GXDA#####). This SDS applies to the 150 products in the GXDA range supplied in 0.01M phosphate-buffered saline, pH 7.4. The applicable SKUs are listed in the annex to this document.
Product form	Mixture – purified immunoglobulin in 0.01M phosphate-buffered saline, pH 7.4.
Relevant identified uses	Laboratory reagent for research use only (RUO). Not for use in diagnostic or therapeutic procedures, or for human or veterinary use.
Uses advised against	Any use other than the identified research use.
Supplier	Assay Genie Ltd www.assaygenie.com Technical support: techsupport@assaygenie.com Sales: sales@assaygenie.com
Registered address	Assay Genie Ltd, 25 Windsor Place, Dublin 2, D02 VY42, Ireland
Emergency telephone	+353 1 563 9720 (Monday–Friday, 08:00–18:00 GMT). This is not a 24-hour emergency line; for medical emergencies contact your local poison centre or emergency services.

SECTION 2: Hazards identification

Classification (CLP/GHS)	Based on available information the product as supplied is not classified as hazardous under Regulation (EC) No 1272/2008 (CLP) or UN GHS. The product is a dilute protein solution in a neutral phosphate buffer and contains no component at a concentration requiring classification.
Label elements	No signal word, hazard pictogram or hazard statement is required for the product as supplied.
Other hazards	No other hazards identified. Under improper handling or excessive exposure the product may cause mild transient irritation of the skin, eyes or respiratory tract. No PBT/vPvB components are known.

SECTION 3: Composition / information on ingredients

The product is a dilute protein solution in a neutral phosphate buffer. No component is present at a concentration that requires classification or disclosure under CLP/GHS. Component concentrations are nominal and may vary slightly between batches.

Component	CAS No.	Concentration	Classification note
Antibody protein (immunoglobulin)	—	0.1–1.0 mg/mL	Not classified
Sodium chloride	7647-14-5	0.8–0.9% (w/v)	Below classification threshold
Disodium hydrogen phosphate	7558-79-4	0.1–0.2% (w/v)	Below classification threshold
Potassium dihydrogen phosphate	7447-40-5	0.01–0.03% (w/v)	Below classification threshold
Water for injection	7732-18-5	Balance	Not classified

SECTION 4: First-aid measures

Inhalation	Not an expected route of exposure. Move to fresh air if aerosols are inhaled and symptoms occur. Seek medical advice if symptoms persist.
Skin contact	Wash the affected area with soap and water. Remove contaminated clothing. If irritation or a skin reaction develops, seek medical advice.
Eye contact	Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do. If irritation persists, seek medical attention.
Ingestion	Rinse mouth with water. Do not induce vomiting. Seek medical advice if a large amount is swallowed.
Most important symptoms	No specific symptoms expected. Mild transient irritation possible on direct contact.
Medical attention	Show this safety data sheet to the doctor in attendance.

SECTION 5: Firefighting measures

Suitable extinguishing media	Water spray, alcohol-resistant foam, dry chemical or carbon dioxide, as appropriate to the surrounding fire.
Special hazards	The product is not flammable. Combustion may emit oxides of carbon and nitrogen.
Advice for firefighters	Wear self-contained breathing apparatus and full protective clothing where required by the surrounding fire.

SECTION 6: Accidental release measures

Personal precautions	Wear gloves and eye protection. Avoid contact with skin and eyes. Ensure adequate ventilation.
Environmental precautions	Do not allow large quantities to enter drains or watercourses.
Methods for containment / cleaning	Absorb spillage with inert absorbent material, place in a suitable container and dispose of in accordance with local regulations. Wipe the area with water.
Reference to other sections	For personal protection see Section 8. For disposal see Section 13.

SECTION 7: Handling and storage

Precautions for safe handling	Handle in accordance with good laboratory practice. Wear appropriate PPE. Do not eat, drink or smoke when using the product. Avoid generating aerosols. Wash hands after use.
Storage	Store at 2–8°C for frequent use, or at –20°C to –80°C for long-term storage. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. See the product datasheet for the SKU-specific storage statement.
Shelf life	Twelve months from the date of receipt under the storage conditions stated above, unless otherwise stated on the product label.

SECTION 8: Exposure controls / personal protection

Occupational exposure limits	None established for the mixture or its components at the concentrations supplied.
Engineering controls	Normal laboratory ventilation is sufficient. Ensure eye wash facilities are available.
Personal protective equipment	Nitrile or latex gloves, laboratory coat and safety glasses. Gloves should be inspected before use and hands washed after handling.
Respiratory protection	Not normally required. Use a suitable respirator if a risk assessment indicates aerosol generation.

SECTION 9: Physical and chemical properties

Appearance	Clear, colourless to pale yellow aqueous solution.
Odour	Odourless or faint.
pH	7.0–7.4.
Freezing point	Approximately 0°C (aqueous).
Solubility	Miscible with water.
Viscosity	Similar to water.
Flammability	Non-flammable (aqueous).
Other properties	Boiling point, flash point, vapour pressure, explosive and oxidising properties: not determined / not applicable to aqueous protein solutions.

SECTION 10: Stability and reactivity

Reactivity / stability	Stable under the recommended storage and handling conditions.
Conditions to avoid	Elevated temperatures, direct sunlight, repeated freeze-thaw cycling.
Incompatible materials	Strong acids and alkalis; strong oxidising and reducing agents.
Hazardous decomposition products	None known under normal conditions of use.

SECTION 11: Toxicological information

Acute toxicity	No toxicological data available for the mixture. Not expected to be acutely toxic at the quantities and concentrations supplied.
Skin / eye	Not expected to be irritant. The buffer is neutral (pH 7.0–7.4). Transient mild irritation possible on direct eye contact.
Sensitisation / CMR	No component is known to be a sensitiser, carcinogen, mutagen or reproductive toxicant at the concentrations supplied.
Specific target organ toxicity	No data indicating specific target organ toxicity. Classification criteria are not met.
Aspiration hazard	Low volatility aqueous solution. Classification criteria are not met.
Routes of exposure	Inhalation of aerosols may cause transient irritation of the upper respiratory tract. Prolonged skin contact may cause transient redness. Direct eye contact may cause transient redness and tearing. Accidental ingestion may cause transient gastrointestinal irritation.

SECTION 12: Ecological information

Ecotoxicity	No data available. No significant environmental effects expected from the small quantities supplied.
Persistence / bioaccumulation / mobility	Not determined.
PBT / vPvB	The mixture contains no components assessed as PBT or vPvB.
Endocrine disrupting properties	No data indicating that the components have endocrine disrupting properties.

SECTION 13: Disposal considerations

Waste treatment	Dispose of contents and container in accordance with local, regional and national regulations. Where material of human or animal origin has been in contact with the product, treat consumables as potentially infectious biological waste.
Contaminated packaging	Dispose of via a licensed waste contractor in accordance with local regulations.

SECTION 14: Transport information

ADR / RID / IMDG / IATA / DOT	Not classified as dangerous goods for transport. No UN number assigned.
UN number / proper shipping name	Not applicable.
Transport hazard class / packing group	Not applicable.
Special precautions	None. Ship with cold packs or on dry ice as required to maintain the storage temperature.

SECTION 15: Regulatory information

EU regulations	This SDS has been prepared in accordance with Regulation (EC) No 1907/2006 (REACH) Annex II, as amended, and Regulation (EC) No 1272/2008 (CLP).
US regulations	This SDS is also intended to meet the format requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200 (HazCom 2012). TSCA, SARA 311/312, SARA 313, CERCLA and California Proposition 65: not applicable.
Chemical safety assessment	No chemical safety assessment has been carried out for this mixture.
Product status	For Research Use Only (RUO).

SECTION 16: Other information

Revision	Version 1.0, 28 July 2026. First issue.
Scope	This SDS covers the 150 GXDA products supplied in 0.01M phosphate-buffered saline, pH 7.4. The Assay Genie GXDA range comprises two formulations and is covered by two separate safety data sheets; check the buffer stated on the product datasheet to identify which applies.
Prepared by	Assay Genie (draft prepared for QA/EHS review).
Disclaimer	The information above relates only to the specific product range and does not constitute a warranty of any kind. It is provided in good faith and is believed to be correct as of the revision date. Composition data are taken from supplier product specifications. It is the user's responsibility to ensure safe conditions of use and to comply with applicable laws.

Annex: products covered by this safety data sheet (150)

This SDS applies to the following Assay Genie SKUs. Products in the GXDA range not listed here are covered by the other GXDA safety data sheet.

GXDA00001	GXDA00003	GXDA00006	GXDA00009	GXDA00011	GXDA00012
GXDA00014	GXDA00016	GXDA00019	GXDA00022	GXDA00025	GXDA00028
GXDA00030	GXDA00033	GXDA00037	GXDA00040	GXDA00043	GXDA00045
GXDA00048	GXDA00051	GXDA00054	GXDA00058	GXDA00062	GXDA00063
GXDA00067	GXDA00069	GXDA00073	GXDA00075	GXDA00077	GXDA00080
GXDA00083	GXDA00086	GXDA00089	GXDA00090	GXDA00094	GXDA00098
GXDA00100	GXDA00104	GXDA00108	GXDA00110	GXDA00114	GXDA00118
GXDA00119	GXDA00121	GXDA00123	GXDA00127	GXDA00131	GXDA00135
GXDA00139	GXDA00142	GXDA00145	GXDA00149	GXDA00153	GXDA00157
GXDA00161	GXDA00165	GXDA00169	GXDA00182	GXDA00186	GXDA00206
GXDA00207	GXDA00208	GXDA00209	GXDA00210	GXDA00211	GXDA00212
GXDA00213	GXDA00218	GXDA00219	GXDA00220	GXDA00221	GXDA00222
GXDA00223	GXDA00224	GXDA00225	GXDA00226	GXDA00227	GXDA00228
GXDA00229	GXDA00230	GXDA00231	GXDA00232	GXDA00233	GXDA00234
GXDA00235	GXDA00236	GXDA00237	GXDA00238	GXDA00239	GXDA00240
GXDA00241	GXDA00242	GXDA00243	GXDA00244	GXDA00245	GXDA00246
GXDA00247	GXDA00248	GXDA00249	GXDA00250	GXDA00251	GXDA00252
GXDA00253	GXDA00254	GXDA00255	GXDA00256	GXDA00257	GXDA00258
GXDA00259	GXDA00260	GXDA00261	GXDA00262	GXDA00263	GXDA00264
GXDA00265	GXDA00266	GXDA00267	GXDA00268	GXDA00269	GXDA00270
GXDA00271	GXDA00272	GXDA00273	GXDA00274	GXDA00275	GXDA00276
GXDA00277	GXDA00278	GXDA00279	GXDA00280	GXDA00281	GXDA00282
GXDA00283	GXDA00284	GXDA00285	GXDA00286	GXDA00288	GXDA00289
GXDA00290	GXDA00293	GXDA00294	GXDA00295	GXDA00296	GXDA00297
GXDA00298	GXDA00299	GXDA00300	GXDA00301	GXDA00302	GXDA00306

— End of Safety Data Sheet —